On June 27, Guardant Health rose 5.08% in regular trading, trading at $150.28/share, with turnover of $177 million. The stock continued its upward trajectory as multiple positive catalysts converged.

On the news front, RBC Capital Markets initiated coverage on June 12 with an Outperform rating and a $185 price target, noting that only approximately 25% of metastatic cancer patients in the US currently receive genomic profiling, positioning Guardant as the market leader best suited to benefit from expanding adoption. Additionally, Guardant360 CDx received FDA approval on June 11 as a companion diagnostic for Boehringer Ingelheim's Hernexeos therapy in HER2-mutant advanced non-small cell lung cancer. These developments follow the company's Q1 results that significantly exceeded expectations, with adjusted EPS of $(0.45) beating the $(0.76) estimate by 40%, and revenue of $301.7 million surpassing the $279.2 million consensus. The company also raised its full-year revenue guidance to $1.30B-$1.32B, above the prior FactSet estimate of $1.27B.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)